
May 12 (Reuters) - Amylyx Pharmaceuticals Inc AMLX.O:
AMYLYX PHARMACEUTICALS ANNOUNCES POSITIVE LONG-TERM RESULTS FROM PHASE 2 HELIOS CLINICAL TRIAL OF AMX0035 IN PEOPLE WITH WOLFRAM SYNDROME
AMYLYX PHARMACEUTICALS INC - AMX0035 WELL-TOLERATED IN ALL PARTICIPANTS
AMYLYX PHARMACEUTICALS INC - EXPECTS CASH RUNWAY THROUGH END OF 2026